Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Implant infection, rupture and capsular contracture

Essential points for quick revision.

Saved on this device

Synopsis

Assess symptoms around a reconstructed breast implant, distinguish urgent infection from structural complications and investigate late swelling without missing capsule-associated malignancy.

  • A painful red reconstructed breast, fever, wound discharge or implant exposure needs prompt reconstructive-team assessment. Suspected deep pocket infection requires antimicrobial treatment and a source-control decision; a cellulitis prescription alone is insufficient.
  • For a persistent new peri-implant seroma more than one year after insertion, arrange urgent ultrasound and purposeful sampling for cytology and appropriate haematopathology, specifically raising BIA-ALCL. Do not simply drain and discard the fluid.
  • Ultrasound is the initial implant-complication study; equivocal rupture findings warrant dedicated non-enhanced implant MRI. Painful firmness and distortion may represent contracture but a new fluid collection or mass needs separate assessment.

Key red flags

Deep infection and threatened coverage

Look for spreading warmth and erythema, escalating pain, wound discharge, dehiscence and visible or threatened implant exposure. Fever, tachycardia, hypotension or systemic deterioration increase urgency, but a patient can have a clinically important infected pocket without all of those signs. Inspect the quality of the covering skin and consider an underlying collection. Contact the responsible breast or plastic surgical service promptly and use emergency assessment for systemic illness. A superficial skin response to antibiotics does not prove that a deeper collection or contaminated device has been dealt with.

Investigation priorities

01
Ultrasound and directed peri-implant samplingFirst step

For late persistent swelling, obtain urgent expert ultrasound to identify fluid, a capsular mass and relevant nodes. Arrange image-guided aspiration with the laboratory pathway agreed in advance; clearly state concern for BIA-ALCL.

Management branches

Worked caseAn infected pocket with an exposed implant

Twelve days after reconstruction, a woman has increasing pain, purulent drainage and a small wound opening with the implant visible. Ultrasound shows peri-implant fluid.

  1. The assessing clinician obtains observations, checks the remaining skin coverage and contacts the reconstructive surgeon urgently. The combination of purulent fluid and exposure establishes a source-control concern even though her blood pressure is currently normal; she is admitted rather than given an isolated community cellulitis course.
  2. The surgical team provides antimicrobial treatment and takes her to theatre for drainage, debridement and removal of the exposed infected device after assessing the pocket and non-viable covering tissue. Fluid and tissue are sent for microbiology. Keeping the implant would leave the identified source and inadequate coverage unresolved in this case.

Key medicines

Flucloxacillin 500 mg oral capsules — superficial cellulitis onlyFor a stable adult with normal renal function, 500 mg orally four times daily for 5 days is a selected NG141 example; the guideline range is 5–7 days. Review improvement within 2–3 days and sooner for deterioration. This example totals 2 g/day. Bristol Laboratories capsules should be taken at least 1 hour before or 2 hours after food with a full glass of water; do not lie down immediately afterwards.Do not use with beta-lactam hypersensitivity or previous flucloxacillin-associated jaundice/hepatic dysfunction. It is not appropriate for known or suspected MRSA. Suspected deep infection, exposure or systemic illness requires urgent surgical care. If creatinine clearance is below 10 ml/min, reduce the dose or extend the interval; the selected SmPC gives a severe-renal-impairment maximum of 1 g every 8–12 hours. Review methotrexate toxicity risk and monitor INR with warfarin. Liver injury may be delayed; concomitant paracetamol can increase high-anion-gap acidosis risk, especially with renal failure, sepsis or malnutrition.
Open full textbook Answer 2 questions
Sources and review status9 sources · checked 8 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 8 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom